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Study Objective
Little is known regarding trends in poisonings  
within the transgender community. We set out  
to review medical encounters managed by a 
medical toxicologist and provide descriptive data  
in trends among types of exposures within the 
transgender demographic. 
Methods
The Toxicology Investigators Consortium (ToxIC) 
database was created in 2010 by the American 
College of Medical Toxicology (ACMT) to compile 
data recorded by medical toxicologists. In January 
2017 the data field for transgender (and, if 
transgender, male to female or female to male)  
was added to the ToxIC form. Between January, 
2017–December, 2020 a retrospective ToxIC 
database review of transgender cases including 
descriptive demographics was performed.
Results
There were 195 transgender cases. Among these, 
61.5% (N=120) were female-to-male, 32.8% (N=64) 
were male-to-female, and 5.6% (N=11) were gender 
nonconforming. In regards to race, 63.1% (N=123) 
were Caucasian, 6.2% (N=12) Black/African American, 
3.6% (N=7) Asian, 2% (N=4) mixed race, 1% (N=2) 
American Indian/Alaskan Native, 0.5% (N=1) Native 
Hawaiian or Pacific Islander, and 23.6% (N=46) 
unknown. In regards to ethnicity, 7.2% (N=14) of 
cases were Latino/Hispanic, 62.6% (N=122) not 
Latino/Hispanic, and 30.2% (N=59) unknown. Of 
the 195 transgender cases, 49.7% (N=97) were 13-18 
years old, 46.2% (N=90) 19-65 years old, 3.1% (N=6) 
7-12 years old, and 1% (N=2) 66-89 years old. In this 
cohort there were no reported deaths.
Overall, 88.2% (N=172) of the poisonings involved 
pharmaceutical drugs – 98.3% (N=169) of which 
were intentional ingestions. Twenty-one percent 
(N=41) were analgesics, 20% (N=39) antidepressants, 
8.7% (N=17) anti-cholinergic/anti-histamines, 7.2% 
(N=14) antipsychotics, 7.2% (N=14) anticonvulsants/
mood stabilizers, 4.6% (N=9) cardiovascular 
medications, 4.1% (N=8) opioids, 3.6% (N=7) 
ethanol; 2.6% (N=5) sympathomimetics, 2.6% (N=5) 
household substances, 2% (N=4) cough & cold 
medications, 2% (N=4) sedative/hypnotic/muscle 
relaxants, 1.5% (N=3) other pharmaceuticals, 1% 
(N=2) psychoactive substances, 1% (N=2) diabetic 
medications, 1% (N=2) caustic ingestions, 1% (N=2) 
toxic alcohols (specifically ethylene glycol and 
isopropanol); 0.5% (N=1) metals, 0.5% (N=1) herbals/
dietary supplements/vitamins, 0.5% (N=1) GI 
medications, 0.5% (N=1) envenomations; 0.5% (N=1) 
chemotherapeutic/immune medications, 0.5% 
(N=1) antimicrobials, 0.5% (N=1) anticoagulants, and 
5.1% (N=10) unknown or not reported.
Conclusion
Among transgender patients with poisonings 
reported to the ToxIC registry, the majority were 
adolescent Caucasians who ingested either analgesic 
or psychotropic medications. These data may be 
helpful to develop poisoning prevention practices in 
this vulnerable population. 
195 transgender cases
 61.5% female-to-male 
 32.8% male-to-female 
 5.6% gender nonconforming
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